Form Type:  SC 13G
Filing Date:  9/10/2019 
CIK:  0001759425 
Address:  950 TOWER LANE, SUITE 1050 
City, State, Zip:  FOSTER CITY, California 94404 
Telephone:  650-667-4085 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.64 (-3.25%)  
Trade Time: 
Jul 10  
Market Cap: 
Trade MIRM now with 

© 2020  
Description of Business
We are a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. We focus on diseases for which the unmet medical need is high and the biology for treatment is clear. Our pipeline consists of two clinical-stage product candidates with mechanisms of action that have potential utility across a wide range of orphan cholestatic liver diseases. We are initially developing maralixibat for the treatment of pediatric patients with Alagille syndrome ("ALGS") and progressive familial intrahepatic cholestasis ("PFIC"). Based on improvements in pruritus, or itching, and other outcomes and disease markers observed in Phase 2 clinical trials, we are planning to initiate a rolling submission of a New Drug Application ("NDA"), for the treatment of cholestatic pruritus associated with ALGS in the third quarter of 2020.
Register and access this filing in:     
  EXHIBIT 99.1
  EXHIBIT 99.2